AI vs. doctors: who spots kidney danger from chemo first?
NCT ID NCT07114276
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a machine learning model could predict kidney injury caused by platinum chemotherapy more accurately than doctors. Researchers followed 77 cancer patients receiving cisplatin or carboplatin, tracking their kidney function over time. The goal was to see if the computer model could better forecast acute kidney injury within 14 days or kidney disease within 89 days, compared to clinical judgment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- machine learning model
- What this could lead to
- If successful, this could help doctors identify patients at high risk for kidney damage from platinum chemotherapy, allowing for earlier protective measures.
- What could go wrong
- This is a small, completed study (77 patients) that only tests prediction accuracy, not whether using the model actually improves patient outcomes. The model may not work as well in other populations or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
77 people
The number who actually took part.
- Started
-
Oct 2023
- Finished
-
Nov 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All patients admitted to Wan Fang Hospital during the period of the study. Patients used at least one dose of cisplatin or carboplatin as chemotherapy.
- Ages
-
20 to 89 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients under clinical diagnosis of cancer with treatments including at least taking one course treatment of Cisplatin and Carboplatin from Dec,2022 to July,2026, at least having one serum creatinine data before and after the administration, willing to provide DNA sample and sign the informed consent will be recruited. Exclusion Criteria: * Patients who are young than 20 years old or older than 89 years old, pregnant women, infected by Human Immunodeficiency Virus (HIV), administered by Ifosfamide, couldn't evaluate their kidney function, refuse to provide DNA sample and sign the informed consent will be excluded.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute kidney disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Taipei Medical University Wan Fang Hospital
Taipei, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can colorectal surgery patients go home in two days?
- Can a personal navigator help young cancer patients through treatment?
- Can a smartwatch predict which cancer patients return to hospital?
- Common Anti-Nausea drugs under scrutiny for kidney risk during chemo
- Two-Drug combo aims to stall advanced breast cancer
- Heart attack delay may signal kidney risk after angioplasty